Paul Chamberlain, BSc (Hons), MCOptom, the study’s principal investigator, CooperVision director of research programs. 
BOSTON—CooperVision on Tuesday announced new seven-year findings from its pivotal MiSight 1 day contact lens clinical trial. The company, a world leader in myopia control and management for children, noted that 12 months following treatment cessation, mean axial elongation data indicate no evidence of rebound effect, meaning the myopia control gains are retained. CooperVision debuted the findings of the important study here at a special event as ECPs gathered for the opening of the American Academy of Optometry’s annual Academy meeting.

The international study is the world’s longest continuous running soft contact lens clinical trial for myopia control, the company noted. CooperVision previously reported that MiSight 1 day showed sustained slowing of myopia progression across multiple years of treatment. This was observed in a cohort that wore MiSight 1 day for the study’s first six years as well as the original control group who were switched into MiSight 1 day for three years.

“Our unparalleled research clearly illustrates the tremendous potential of MiSight 1 day for children of different ages and with different levels of myopia, regardless of when they start treatment. With these results, eyecare professionals should be even more confident in prescribing MiSight 1 day,” said Paul Chamberlain, BSc (Hons), MCOptom, the study’s principal investigator and CooperVision director of research programs.

Michele Andrews, OD, vice president, Professional & Government Affairs, Americas.
The latest data analysis goes even deeper to illustrate that MiSight 1 day offers a highly-desired proportional myopia control treatment effect. Abnormal axial length growth slowed by an average of approximately 50 percent with all tested ages (8-17). Because younger children’s myopia progresses faster than in older children, introducing MiSight 1 day at the earliest opportunity may offer the maximum cumulative benefit over time.
In the study’s seventh year, participants were transitioned from MiSight 1 day to a single vision contact lens to evaluate if treatment gains would be retained. Myopic progression then occurred only at anticipated "age-normal" levels—not at an accelerated “catch up” rate that would offset prior myopia control gains. This indicates no rebound effect.
“We saw these children grow into young adults during their seven years in the study. It is personally as well as professionally fulfilling to know that the benefits of treatment are retained. As MiSight 1 day becomes more widely available and as myopia management becomes the standard of care, I hope other eyecare professionals will experience that same joy,” said study investigator Nicola Logan, PhD, professor of optometry and physiological optics, Aston University.

Justin Kwan, senior manager, Myopia Management in the Professional & Academic Affairs group.

MiSight 1 day contact lenses are specifically designed for myopia control and are FDA approved to slow the progression of myopia in children aged 8-12 at the initiation of treatment. In August, MiSight 1 day received approval from the Chinese National Medical Products Administration (NMPA) to become the first indicated product of any type that may slow the progression of axial length.
CooperVision researchers will continue to share the findings of this study at Academy this week.